Unaudited Financial Results of the company for the quarter and half year ended on 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Bio Systems Limited reported its unaudited Q2 FY26 results. Revenue from operations stood at Rs 24.47 lakhs in Q2 FY26, up from Rs 18.05 lakhs in Q1 FY26. For the half year ended September 2025, revenue was Rs 42.52 lakhs compared to nil in the same period last year. Profit after tax for Q2 was Rs 3.94 lakhs and Rs 7.95 lakhs for H1 FY26, against a loss of Rs 0.50 lakhs in H1 FY25. Earnings per share for H1 FY26 was Rs 0.11. The board also appointed Mr. Shashank Kumar as Secretarial Auditor and Mr. Nishant Sharma as Internal Auditor for FY25-26. The statutory auditor issued an unqualified review report.
The results show a clear operational turnaround with revenue resuming and the company moving into profit after near-zero activity a year ago. However, other equity remains negative at Rs (101.82) lakhs and total borrowings of Rs 561.59 lakhs against shareholders' funds of Rs 598.40 lakhs indicate a high debt burden, so the small absolute earnings may not yet drive a meaningful stock reaction.